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Abstract: Autosomal recessive ataxias are much less well studied than autosomal dominant ataxias
and there are no clearly defined systems to classify them. Autosomal recessive ataxias, which are
characterized by neuronal and multisystemic features, have significant overlapping symptoms with
other complex multisystemic recessive disorders. The generation of animal models of neurodegener-
ative disorders increases our knowledge of their cellular and molecular mechanisms and helps in the
search for new therapies. Among animal models, the zebrafish, which shares 70% of its genome with
humans, offer the advantages of being small in size and demonstrating rapid development, making
them optimal for high throughput drug and genetic screening. Furthermore, embryo and larval
transparency allows to visualize cellular processes and central nervous system development in vivo.
In this review, we discuss the contributions of zebrafish models to the study of autosomal recessive
ataxias characteristic phenotypes, behavior, and gene function, in addition to commenting on possible
treatments found in these models. Most of the zebrafish models generated to date recapitulate the
main features of recessive ataxias.
Keywords: zebrafish; hereditary recessive ataxias; neurodegenerative disorders; genetic edition
1. Introduction
Hereditary ataxias are a heterogeneous group of rare neurodegenerative disorders
caused by progressive degeneration of the cerebellum and spinocerebellar tracts resulting in
loss of balance and coordination. Classification of hereditary ataxias has been problematic
due to phenotype overlap and the broad number of syndromes that manifest ataxia as a
common symptom, such as hereditary spastic paraplegias and polyneuropathies. However,
the development of novel molecular techniques has made it possible to classify ataxias
based on genetics [1]. Ataxias can be divided into autosomal dominant, autosomal recessive
and X-linked ataxias [2,3].
Unlike autosomal dominant ataxias [4], autosomal recessive ataxias have been less
well studied. Autosomal recessive ataxias are more difficult to classify because, contrary to
autosomal dominant ataxias, they are not organized with a numerical naming system. The
term spinocerebellar ataxia autosomal recessive (SCAR) was recently used to designate
novel ataxias, but it is based only on locus discovery and it does not include the previously
identified and more frequent recessive ataxias. In addition, many recessive multisystemic
or complex metabolic disorders present ataxia as a symptom [2,3]. There are more than
100 loci related with recessive ataxias. The development of next generation sequencing
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technology helped to classify and discover new recessive ataxias [5]. Autosomal recessive
ataxias are a group of complex neuronal disorders usually showing early onset, involving
central and peripheral nervous systems. They often affect other systems and organs and
cause—among others—symptoms such as: peripheral sensorimotor neuropathy; pyramidal
and extrapyramidal involvement; oculomotor defects; retinopathy; cognitive impairment;
metabolism abnormalities; seizures and hypogonadism [2,6]. The pathogenesis of auto-
somal recessive ataxias is associated with loss of function of the related proteins, which
are involved in a broad number of pathways such as: mitochondrial metabolism and
function; metabolic homeostasis; DNA repair; the cell cycle; RNA processing; protein
folding; synaptic morphology and the synaptogenesis of Purkinje cells [3,7,8].
The use of animal models of neurodegenerative disorders can, at least partially, recapit-
ulate the human disease to help unravel the molecular and cellular mechanisms responsible
and represent a first step in developing therapies for diseases that do not yet have available
treatments [9]. For example, in ataxias, Purkinje cell degeneration and motor deficits were
demonstrated in several mice models [10].
The zebrafish (Danio rerio) shares 70% of its genome with humans [11] and is an
emerging animal model that is gaining popularity in the study of a wide range of medical
conditions, such as cancer [12], neurogenetic diseases [13], psychiatry disorders [14], car-
diovascular illnesses [15] and traumatic injuries [16,17]. Its many advantages include: easy
genetic manipulation; the capacity to perform high throughput drug and genetic screening;
optical transparency that allows for visualizing the central nervous system (CNS) and
cellular processes. In addition, behavioral patterns are measurable and easy to evaluate,
including high order behaviors such as memory, conditioned responses and social behav-
iors [18]. The organization of the CNS of the zebrafish is similar to mammals, including
humans. Moreover, most genes related to neural activity or development show similar
functions in mammals and zebrafish. On the other hand, the zebrafish model has the
advantage of having a reduced CNS complexity, which simplifies functional studies [19].
The development of zebrafish loss of function models is easily achieved by transient
knock-down with antisense morpholinos that block translation or splicing [20]. Permanent
knock-out models are created with mutagens such as N-ethyl-N-nitrosourea (ENU) [21],
transgenesis or genetic edition via the use of TALENs (Transcription activator-like effector
nucleases), zinc finger nucleases or the recently discovered CRISPR/Cas9 techniques [22]
(Figure 1).
In this review, we used the Bird classification [23] of ataxias (which includes recently
discovered ataxias) to search zfin (https://zfin.org/ (accessed on 27 January 2021)) and
PubMed (https://pubmed.ncbi.nlm.nih.gov/ (accessed on 27 January 2021)) databases
for zebrafish models targeting genes that cause recessive disorders with cerebellar ataxia
among their clinical manifestations. These data are compiled in Supplemental Table S1.
We discuss the zebrafish models created for the more common recessive ataxias, recessive
ataxias that are relatively more uncommon (only present in a few families), and recessive
disorders that cause abnormalities of cerebellar development and prominent ataxia. The
molecular basis and relevant clinical data of the diseases discussed in the present review are
summarized in Table 1 (more frequent autosomal recessive ataxias in green, less frequent
autosomal recessive ataxias in blue and recessive inherited disorders related to ataxia
in orange).
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Figure 1. Main techniques for generating zebrafish loss of function models.
Table 1. Summary of molecular mechanisms and main clinical features of the ataxias discussed in this article.
Disease Gene Protein Function Clinical Features Other Than * References
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ATG5 Autophagy Mental retardation,developmental delay [33]
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Table 1. Cont.
Disease Gene Protein Function Clinical Features Other Than Ataxia * References
Spastic paraplegia











CWF19L1 Cell Cycle Control Developmental delay, mentalretardation [35]
EAST syndrome KCNJ10 Potassium channel
Short stature, epilepsy, sensorineural
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SCAR7: Slowly progressive spasticity
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UBA5 Ubiquitin-like Cataracts, demyelinating sensorimotorneuropathy [45]
Galloway-Mowat
syndrome WDR73 Unknown
Intellectual disability, short stature,
microcephaly, facial dysmorphism,
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CA8 Unknown Mental retardation quadrupedal gait [51,52]




renal cysts, polydactily, hepatic fibrosis
[53]
Pontocerebellar
hypoplasia Several genes Diverse functions
Hypoplasia of the cerebellum or the




* Cerebellar ataxia is a feature of all the disorders in this table. Not all listed clinical manifestations are necessarily present in every patient
with the disorder. EAST syndrome: epilepsy, ataxia, sensorineural deafness and tubulopathy.
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2. Materials and Methods
Articles were found in the zfin database (https://zfin.org/ (accessed on 27 January 2021))
by searching for zebrafish models of genes that cause recessive ataxias as described in the
classification of Bird [23] and some recessive disorders that have prominent ataxia.
The PubMed database (https://pubmed.ncbi.nlm.nih.gov/ (accessed on 27 January 2021))
was used to find additional models related to these diseases by searching for “zebrafish”
and “name of the disease”. The articles included in this review were published before
27 January 2021.
3. Results
The genes responsible for the diseases discussed here are implicated in a broad
number of signaling pathways and cellular processes that are summarized in Figure 2. In
the following sections, we will review the main findings obtained with zebrafish models
for each of these genes.
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3.1. Autosomal Recessive Cerebellar Ataxias
• Ataxia-telangiectasia (AT).
AT is an in antile onset multi ystemic diseas pr duced by mutations in the ATM gene
(ataxia-telangiect sia mutated), which is volved in cellular responses to DNA dam ge
and c ll cycle contr l [24].
The first ataxia-tela iectasia zebr fish model was enerated with morph linos a d
reproduced the role of ATM in the DNA da age respo se [55]. Atm morphants exhibit nor-
mal development but when a radiation dose of 8 Gy was applied to 6 hpf atm morphants,
abnormal development with retardation was observed. Atm irradiated morphants exhib-
ited no pigmentation, a lack of yolk extension, and extreme ventral body curvature and
died by 72 hpf. Higher amounts of atm morpholino, combined with radiation, increased
mortality of embryos by 48 hpf and induced more severe curvature and absence of yolk
extension phenotypes. This phenotype caused by irradiation was not seen in embryos
injected with a control morpholino, which means that deficiency in atm leads to increased
radiosensitivity [55].
Recently, an atm zebrafish mutant was developed which did not show neurodegenera-
tive defects but developed exclusively as infertile males [56]. Infertility is a characteristic
of some AT patients. Disabling the apoptosis pathway ith a p53 mutation rescued the
all-male phenotype, but not infertility. In addition, atm-p53 double mutants showed quick
tumor formation, w ich suggests t t atm acts as a tumor suppressor and is involved
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in maintaining genomic stability. Surprisingly, atm mutant embryos did not display the
radiosensitivity observed in atm morphant embryos. This is probably due to compensation
mechanisms [56]. These results indicate that zebrafish models of atm can be used to analyze
the function of ATM in the DNA damage response but not for neurodegeneration.
• Boucher–Neuhäuser syndrome and spastic paraplegia type 39 (SPG39).
Mutations in the PNPLA6 (patatin like phospholipase domain containing 6) gene cause
SPG39 and Boucher–Neuhäuser syndrome which express similar symptoms [25]. Other
syndromes that have been related with mutations in PNPLA6 include: (i) Oliver–McFarlane
syndrome, the features of which consist of trichomegaly, congenital hypopituitarism and
retinal degeneration with choroidal atrophy; (ii) Laurence–Moon syndrome, which presents
in a similar manner, though with progressive spinocerebellar ataxia and spastic paraplegia,
and without trichomegaly [57].
Pnpla6 zebrafish morphants have been shown to exhibit a curly tail that is dose-
dependent. The head–tail distance was shorter in morphants and they also had abnormal
eye development and reduced otic vesicle size. Morphant eyes were smaller than in controls
and some of them had unclosed eye fissures [57,58]. In addition, some pnpla6 morphants
showed midbrain–hindbrain boundary defects, swelling of the pericardium, reduced heart
rate and reduced blood flow [58]. Normal PNPLA6 human mRNA was able to rescue the
phenotype but not PNPLA6 human mRNA without the catalytic domain. This means that
the phenotype in pnpla6 morphants was due to reduced esterase activity [58]. Likewise,
co-injection with human mRNA with known mutations of SPG39, Oliver–McFarlane syn-
drome or Laurence–Moon syndrome, did not rescue the phenotype [57]. Motor neurons
and spinal motor neuron numbers were reduced in pnpla6 morphant zebrafish. Aberrant
motor axon branching was also observed, which seemed to be truncated and failed to join
the ventral muscles. An increase in apoptosis was observed in this model, especially in
the CNS, that was not rescued with co-injection of p53 morpholino. Cell cultures of pnpla6
morphant spinal neurons were performed to confirm that the cause of impaired motor
neuron development was not the presence of a deformed body. Chimeric embryos trans-
planted with one cell stage pnpla6 morphant cells also developed axon defects. Mauthner
neurons, interneurons and sensory neurons showed no morphological differences in pnpla6
morphants. BMP (bone morphogenetic protein) signaling was studied by blocking the
kinase activity of BMP receptors with dorsomorphin, which resulted in phenotype rescue
in pnpla6 morphants. This indicates that BMP was overexpressed in pnpla6 knock-down
and that this caused at least part of the morphant phenotype [58]. Although these results
revealed the neurological consequences of pnpla6 dysfunction and a relation with BMP
overexpression, it is necessary to develop a mutant zebrafish model to see if this will
reproduce the phenotype observed with morpholinos.
• Marinesco–Sjögren syndrome.
Marinesco–Sjögren syndrome is a multisystemic early onset disorder caused by muta-
tions in the SIL1 (SIL1 Nucleotide Exchange Factor) gene, which encodes a nuclear exchange
factor for the endoplasmic reticulum resident chaperone BiP (binding immunoglobulin
protein) [26].
Zebrafish morphants for sil1 showed abnormal shape and small eyes. Birefringence
assays revealed abnormal skeletal muscle structure at 4 dpf in morphant embryos. The phe-
notype was rescued by the co-injection of sil1 wild type mRNA. Histological examination
revealed deformed beta-dystroglycan expression at myosepta with a less clear V-shaped
structure and disturbed formation in sil1 morphants. Reduced numbers of Purkinje cells
were observed in sil1 morphant embryos in comparison with controls. Interestingly, sil1
morphants displayed an increase in levels of BiP, the lipidated form of Lc3 (light chain 3)
and caspase 3, which are markers associated with endoplasmic reticulum stress, autophagy
and apoptosis, respectively [59].
Sil1 deficiency in peripheral nerves and neuromuscular junctions was also studied
using sil1 morpholino knock-down in zebrafish. Sil1 morphants demonstrated disrupted
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synapse formation along the vertical myosepta, with remarkable disorganization of presy-
naptic branching across the muscle fibers of the myotomes. Analysis of myelinating
Schwann cells did not show significant differences between sil1 morphants and control
zebrafish [60].
These morphant models revealed neural damage, abnormalities in the skeletal muscle
and neuromuscular junctions, and activation of endoplasmic reticulum stress, autophagy
and apoptosis, which are features of Marinesco–Sjögren patients. The development of
a mutant zebrafish model will assist in the search for treatments and confirm the mor-
phant phenotypes.
• Spinocerebellar ataxia autosomal recessive type 20 (SCAR20).
SCAR20 is caused by mutations in the sorting nexin 14 gene (SNX14), which is required
for autophagosome clearance [27].
Snx14 zebrafish morphants displayed loss of neural tissue volume and reduced num-
ber of Purkinje cells that was rescued with co-injection with human SNX14 mRNA. In
addition, morpholino injection in a reporter line that expressed GFP in the hindbrain
revealed a significant reduction in hindbrain size in morphant embryos. An increase
in apoptosis across the neural tissue was also seen. Transmission electron microscopy
analysis of snx14 morphant neural cells also revealed an accumulation of autophagic struc-
tures. These data suggest that snx14 mutations caused neuronal cell death associated with
impaired autophagic degradation and apoptosis [27].
Surprisingly, a more recent study using snx14 morpholinos in zebrafish did not detect
morphological defects or motor neuron abnormalities. In the same study, an snx14 zebrafish
knock-out model was examined, and no morphological or neuronal abnormalities were
detected, not even when maternal zygotic mutants were analyzed. Behavioral analysis
also showed that mutant snx14 zebrafish did not develop a locomotor phenotype. As
SNX14 mutations had been reported to disrupt neutral lipid metabolism, lipids from 4 dpf
zebrafish were extracted and analyzed through total fatty acids lipidomic profiling. It was
observed that total fatty acids from neutral lipids (both saturated and unsaturated) were
elevated in snx14 knock-out embryos in comparison with wild type and heterozygous
embryos. These results confirm that SNX14 has a conserved role in lipid biogenesis [61].
The discrepancies in these studies could be because Bryant et al. [61] used sub toxic
doses of morpholinos. Morpholinos are only considered reliable when a mutant model
supports morpholino findings due to the previously observed off target effects of mor-
pholinos [62]. In addition, the premature stop codon of mutants resulted in a nonsense
mediated decay that upregulated homologous gene sequences that rescue the phenotype.
The consequence of the mutation at the protein level could not be demonstrated in zebrafish
because there was no SNX14 antibody available that could react with the corresponding
zebrafish protein [61].
• Ataxia with isolated vitamin E deficiency (AVED).
AVED is caused by mutations in the α tocopherol transfer protein (TTPA) gene which
is responsible for the distribution of vitamin E [28].
Ttpa is expressed in the zebrafish brain, eye and tailbud. Experiments with mor-
pholinos in zebrafish showed significant developmental defects at 1 dpf along the an-
terior/posterior axis, with truncated tail and brain and eye malformations. However,
time lapse analysis reported normal development during blastula formation, epiboly and
gastrulation until 12 hpf, when the tppa morphant eye began to display tissue darkening,
indicating the initiation of improper head growth. Co-injection with a p53 morpholino did
not affect the phenotype [63].
Previous studies with a vitamin E-deficient diet in adult zebrafish caused a decreased
startle response that suggested the occurrence of neurological defects. Embryos produced
by zebrafish E depleted adults displayed increased mortality and morphological abnor-
malities such as cranial malformations, a bent anterior–posterior axis, pericardial edema,
swim bladder malformations and yolk-sac edema [64,65]. Surviving vitamin E deficient
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embryos of 24 hpf had somite malformations and stunted fin formation. At 48 hpf embryos
developed acute pericardial and yolk sac edema. Collagen sheath notochord markers
col2a1a (collagen, type II, alpha 1a) and col9a2 (collagen, type IX, alpha 2) showed bent
axes. Surprisingly, it was demonstrated that a vitamin E deficient diet did not affect
the localization or expression of ttpa but affected brain structure. In addition, tppa was
found to be expressed at 24 hpf in the midbrain–hindbrain boundary and pax2a (paired
box 2a) (which defines the midbrain–hindbrain boundary) expressed a diffused signal at
12 and 24 hpf [65]. Future studies with mutants may support the discoveries made with
morpholinos and with a vitamin E deficient diet.
• Wolfram syndrome (WFS).
WFS is a juvenile progressive neurodegenerative disorder caused by mutations in
WFS1, which encodes the wolframin protein. This is an endoplasmic reticulum membrane-
embedded protein related to membrane trafficking, endoplasmic reticulum stress and
calcium homeostasis [29,30].
Zebrafish have two paralogous genes of WFS1, wfs1a and wfs1b. The first knock-
down of wfs1b was created during an assessment of genes that are relevant to diabetes
type 2. Wfs1b knock-down caused a reduction in pancreatic β-islet cells and reduced insulin
expression, suggesting that WFS1 is involved in glucose homeostasis [66].
A broader study of zebrafish models was performed by Cairns [67]. Morpholinos for
wfs1a and wfs1b caused abnormal eye, brain and otoliths, although the wfs1b phenotype
was more pathological. Co-injection of the two wfs1 morpholinos caused lethality in most
embryos and p53 morpholino co-injection did not rescue the phenotype. CRISPR/Cas9
models of wfs1a and wfs1b genes displayed delayed development and smaller otoliths.
Wfs1 knock-outs, particularly the wfs1b knock-out, showed significant delay in neuronal
growth. At 24 hpf, wfs1b displayed shortened motor axons that seemed to be corrected at
48 hpf. Expression of acetylcholine receptors developed normally in both wfs1 knock-outs,
indicating that muscular growth was normal. Acetylcholinesterase activity was reduced
in wfs1a and wfs1b knock-out embryos, which suggested reduced brain activity, but only
was reduced in the wfs1b knock-out at 12 months, suggesting defective neurogenesis in
wfs1b knock-out fish. Moreover, mutants had a smaller cerebellum than the wild types.
Spontaneous movements of wfs1b knock-out zebrafish were significantly higher at 24 hpf
and significantly lower at 48 hpf, as compared to both controls and wfs1a knock-outs.
As no differences were detected in the muscle fiber structure, this was associated with
problems related to neuronal signaling in response to tactile stimulation. Mitochondrial
trafficking was affected in both wfs1 knock-outs and mitochondrial respiration was reduced
in the wfs1b knock-out. Mitochondrial complex I protein expression was reduced in
wfs1a and wfs1b knock-out whole embryos and muscle and also in the brain in wfs1b
knock-out embryos. However, Ca2+ uptake and mitochondrial DNA levels remained
normal in both wfs1 knock-outs. Heat shock—to induce endoplasmic reticulum stress—
increased the death rate in the two wfs1 knock-outs, suggesting increased apoptosis due
to increased endoplasmic reticulum stress response. BiP protein expression was shown
to be upregulated in both heat shocked and untreated wfs1 knock-outs. Wfs1b knock-out
adult zebrafish displayed less locomotion when they were isolated in order to record their
behavior, which suggested increased anxiety. Wfs1b knock-out adults had a significantly
lower blood glucose level and lower fertility than wfs1a and wild type fish. In addition,
both knock-outs had a significantly lower number of retinal ganglion cells than wild
type fish at 4 months and this number decreased even more at 12 months. Wfs1b retinal
ganglion cell numbers were also significantly lower than in wfs1a. Less eye movement
and a thinner optic nerve were also observed in the wfs1b knock-outs at 12 months. The
fact that wfs1b displayed the most severe phenotype, replicating some of the symptoms of
wolfram syndrome patients, could be due to its expression in eyes and neural tissue, unlike
wfs1a which was only found to be expressed in muscle tissue [67]. The use of these models
reproducing the pathological mechanisms of patients with WFS may help to find a therapy
to Wolfram syndrome.
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3.2. Less Frequent Autosomal Recessive Ataxias
• Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract (PHARC).
PHARC is produced by mutations in ABHD12, which encodes the abhydrolase domain
containing protein 12, an enzyme related to endocannabinoid and phospholipid metabolism
and that has essential functions in the central and peripheral nervous systems [31].
A morpholino for the ABHD12 gene was generated as part of a study on neuropathy
candidate genes related to Charcot–Marie–Tooth disease. Abhd12 morphant embryos had
aberrant motor neuron axon extension, pathfinding and branching, with an abnormal
morphology of peripheral neurons [68].
In a more recent study, Abhd12 zebrafish morphants injected with a splice block mor-
pholino displayed two phenotypes: mild and moderate. The moderate phenotype included
severe microphthalmia, microcephaly and reduced body length due to a significant re-
duction in head size. From 3 dpf, both morphant phenotypes did not have spontaneous
free-swimming activity. The moderate phenotype did not display any locomotor activ-
ity in a touch-evoked escape response and mild phenotype animals exhibited impaired
locomotor activity similar to ataxia. None of these phenotypes were rescued after p53
morpholino co-injection. Axonogenesis and motor neuron axon outgrowth was normal
in abhd12 morphants at 3 dpf. However, myelination of the axonal tracks was severely
impaired in abhd12 morphants at 5 dpf. Neuromasts suffer a large reduction in the ante-
rior and posterior lateral line and auditory system in comparison with controls. Normal
Purkinje cell differentiation was observed, while the morphology of the Purkinje cell layer
was affected. A strong impairment of retinal architecture and stratification, absence of
lens clarification and a high decrease in retinotectal projections was also found in abhd12
morphants. Injection of a translation block morpholino caused a severe phenotype with
exacerbation of morphological symptoms, a curved tail and the absence of spontaneous
swimming. Co-injection with abhd12 mRNA of wild type zebrafish embryos or human
ABHD12 mRNA rescued the phenotype of morphant embryos. However, co-injection with
human ABHD12 mRNA encoding one missense or nonsense mutation associated with
PHARC could not restore the normal phenotype [69]. The molecular consequences of
blocking translation seemed to be worse than when blocking mRNA splicing. This may be
due to the different biological role of some parts of the truncated protein.
These models reproduced several of the symptoms of PHARC patients, such as ataxia,
disruption of retinal architecture and a reduction in mechanosensory hair cells in the inner
ear and lateral line. However, it is necessary to generate mutant models to confirm that
these findings were not caused by off-target effects and to search for therapies.
• Cayman ataxia.
Cayman ataxia is a recessive congenital ataxia restricted to the Grand Cayman Island.
Cayman ataxia is caused by mutations in the ATCAY gene, which encodes a neuronal
protein called Caytaxin [32].
Atcay morphants displayed reduced motor axon length in a dose-dependent manner
at 72 hpf. This phenotype was rescued with mouse atcay mRNA and also by mouse VAchT
(vesicular acetylcholine transporter) mRNA, which acts downstream of acetylcholine syn-
thesis and release. This indicates that atcay regulates neurite outgrowth through cholinergic
signaling. Interestingly, knock-down of chat (choline acetyltransferase, which produces
acetylcholine) or acl (ATP citrate lyase, an enzyme that produces acetyl-CoA for lipoge-
nesis, cholesterol genesis and acetylcholine synthesis in the citosol) genes also caused
shorter motor neuron axons. Primary motor neurons from the 18 somite stage of zebrafish
embryos were isolated. Neurite outgrowth could be rescued by supplying carbachol, a
cholinergic agonist. However, atropine (a muscarinic receptor) application in atcay, acl and
chat knock-downs inhibited neurite outgrowth in vitro, this phenotype was not rescued
by carbachol. These data confirm that atcay functions through muscarinic acetylcholine
receptors and the MAPK (mitogen-activated protein kinase) pathway to regulate neurite
outgrowth. The subcellular location of Chat changed in atcay and acl morphants, with Chat
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accumulating in the cell bodies of motor neurons. Chat accumulation in atcay morphants
could be rescued with mice Atcay mRNA co-injection. Knock-down of chat in zebrafish
inhibited acetylcholine neurotransmission and caused enlargement of acetylcholine recep-
tor clusters to compensate for the loss of cholinergic signaling. Interestingly, atcay and acl
morphants also showed an enlargement of acetylcholine receptor clusters. Enlargement
of the acetylcholine receptor clusters in atcay morphants was rescued by VAchT mRNA
co-injection. In addition, loss of acetylcholine signaling also affected the development of
muscle fibers in atcay morphants, which showed abnormal structures of slow and fast
muscles. These data suggest that Atcay regulates cholinergic signaling at the neuromus-
cular junction and that cholinergic signaling is required for the proper development of
neuromuscular connections. Motor behavior was also affected in atcay morphants, which
displayed a deteriorated escape response after touch stimulus and a delay in spontaneous
movement. This defect was rescued by Atcay and Vacht mRNA co-injection. Acl and chat
morphants had similar behavior phenotypes [70]. This study helped to elucidate that atcay
has a role in motor neuron development and this model was used to show that carbachol
treatment rescues neurite outgrowth in atcay morphant cells. Thus, this study might be a
first step in the development of a treatment that requires confirmation through the use of
an atcay mutant.
• Spinocerebellar ataxia autosomal recessive type 20 (SCAR25).
Mutations in the ATG5 gene are related with congenital childhood ataxia with mental
retardation, and developmental delay. ATG5 (autophagy protein 5) is an E3 ubiquitin ligase
that is essential for autophagosome elongation. Patients with mutations in ATG5 show
defects in autophagy [33].
Atg5 morpholino knock-down in zebrafish resulted in high mortality (between 40 and
60%). Zebrafish showed: smaller and incomplete head and eyes; otolith deformities; an
abnormal heart structure with less blood and congestion in the ventral common cardinal
vein; smaller body; decreased tail and yolk extension; somite deficiency. Therefore, atg5
seems to be involved in the formation of essential embryonic structures, mainly in the
neural system. The phenotype was rescued with co-injection of wild type atg5 mRNA.
Interestingly, atg5 overexpression led to 30% mortality, development retardation, an absence
of body pigments, small otoliths, ventralized optic vesicles, reduced brain development,
insufficient differentiation of the trunk and abdomen, and diminished clarity of the yolk
and yolk extension. Surprisingly, atg5 mRNA levels were upregulated in morphants and
downregulated after atg5 overexpression. In contrast, the atg5 protein was reduced in the
morphants and increased in embryos with mRNA overexpression. These data suggest
that the Atg5 protein can regulate atg5 transcription in a feedback inhibitory loop. In
addition, LC3B (light chain 3B), an autophagy marker, showed reduced protein expression
in atg5 morphants and increased expression upon atg5 mRNA overexpression, which
demonstrated that the autophagy pathway is regulated by atg5 during neural development
in zebrafish embryos. Analysis of mRNA expression of several genes involved in neuronal
development showed upregulation in atg5 morphant embryos and downregulation of
the same genes in embryos injected with atg5 mRNA. Rapamycin treatment, which is a
reagent for autophagy induction, produced a similar embryonic phenotype to that of atg5
morphants [71].
A more recent study using morpholinos of the autophagy related genes atg5, atg7
and becn1 in a zebrafish autophagy reporter line showed inhibition of autophagosome
accumulation in vivo. Immunoblots of protein lysates from primary cell cultures of the
three morphants revealed blocked Lc3-II conversions, which means that autophagy was
inhibited. Atg5, atg7 (autophagy protein 7) and becn1 (beclin1) morphants displayed a
similar phenotype at 2 dpf, with small heads and eyes, twisted body shapes and cardiac
defects such as pericardial edema, defective blood flow through the heart, defective heart
looping, enlarged atria and a linearized heart. Knock-down of these genes in a p53 zebrafish
mutant line resulted in the same phenotype. Atg5, atg7 and becn1 1 dpf morphants showed
an increase in apoptosis. The fact that 40% of atg5 morphants and less than 10% of becn1 or
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atg7 morphants survived more than 10 dpf and that the morpholino effects last less than
5 days, means that autophagy during the firsts days of development is essential for long
term fish viability. Atg5 and atg7 showed significantly reduced numbers of autophagosomes
at 3 dpf throughout the entire heart in comparison with wild type embryos. Histology
of 3 dpf morphant hearts revealed enlarged atria with an accumulation of blood cells
and incorrect looping compared with controls. The use of a reporter line that labels
endothelial cells, including the vasculature, blood cells, and endocardial cells, showed
that autophagy morphants had no vasculature defects at 3 dpf. Misexpression of vcan
(Versican), bmp4 (bone morphogenetic protein 4), and notch1b (notch receptor 1B)—genes
that are necessary for atrioventricular valve development—was reported in morphants
(mainly in the ventricle), while in controls the expression of these genes was confined to
the atrioventricular valve. These data suggest that autophagy gene regulatory networks
are necessary for correct cardiac morphogenesis. Microarray analysis of morphant hearts
confirmed the altered expression of decisive genes for heart development and function.
Most of the altered genes in autophagy morphants were transcriptional regulators or had
roles in fundamental cellular pathways, such as the cell cycle, metabolism, and mitosis [72].
Interestingly, atg5 function has been also shown to be necessary for caudal fin regen-
eration. Atg5 knock-down was able to block regeneration of the caudal fin and induce
degeneration of the existing blastema in adult zebrafish 2 days after caudal fin amputa-
tion. Atg5 defective fin tissues showed increased apoptosis and reduced proliferation. A
preosteoblast marker and osteocalcin showed impaired expression in atg5 morpholino
treated fin tissues, which shows that cell differentiation was also compromised [73]. Atg5
function during regeneration was also assessed in a zebrafish model of extraocular muscle
regeneration, in which the lateral rectus muscle was surgically removed [74]. Delivery
of an atg5 morpholino by electroporation significantly reduced muscle regeneration [74].
These studies indicate that Atg5 plays a key role in tissue regeneration.
In zebrafish models of polycystin-2 deficiency and polycystic kidney disease, co-
injection of an atg5 morpholino led to an increase in the cystic phenotype [75,76].
Finally, in a zebrafish model of Parkinson’s disease, depleted atg5 expression was
shown to aggravate the Parkinson’s disease phenotype, with a further reduction in the
number of dopaminergic neurons and a worsening of locomotor behavior. In contrast, atg5
overexpression in this model restored the number of dopaminergic neurons at levels that
were equal to those of the wild type and led to recovery of locomotion. Knock-down of
atg5 caused an upregulation of β-syn, (β synuclein), PINK1 (PTEN induced kinase 1) and
parkin proteins, which have been related to Parkinson’s disease. These data suggest that
atg5 is probably involved in the transcription of genes related to Parkinson’s disease and
neurodegeneration [77].
Atg5 has a role during development, autophagy, heart function, regeneration and
neural development in zebrafish. As with other morphant models, it is important to
confirm its role in mutant models, which could also be used to search for treatments.
• Spastic paraplegia type 76 (SPG76).
Mutations in CAPN1 (calpain-1) have been associated with SPG76, spastic paraplegia
accompanied with ataxia and spastic ataxia. CAPN1 encodes calpain-1 catalytic subunit, which
has an essential role in neuronal plasticity, migration and microtubular regulation [34].
CAPN1 is present in zebrafish in two forms: capn1a and capn1b. Morphants for both
calpain genes in zebrafish have been developed. Capn1a—but not capn1b—morphants
resulted in several developmental defects at 2 dpf, such as: a hydrocephalic brain, small
eyes, yolk sac extension, pericardial edema, and an aplastic swim bladder. mRNA rescue
with human CAPN1 failed because human protein was detected at 24 hpf, but not at 48 hpf,
while only the zebrafish protein was detected later at 48 hpf. Examination of the CNS
revealed motor neuron disorganization, migration defects of the trigeminal motor nucleus
and of the facial branchiomotor neuronal cell bodies, which had not fully migrated from
rhombomere 4 to 6. Moreover, the vagal motor neurons had an abnormal positioning and
spacing, suggesting defects in cell motility. Disruption in the microtubule network in optic
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tectum and cerebellum was also observed. Furthermore, microtubules in the motor neuron
axons were thinner and more disorganized [78].
This morpholino study seems to demonstrate that capn1 has a critical role in neural func-
tion, but it is still necessary to analyze the effects of capn1 mutations on locomotion. Moreover,
the development of a mutant line is always crucial to confirm a morpholino phenotype.
• Spinocerebellar ataxia autosomal recessive type 17 (SCAR17).
A splice mutation in the CWF19L1 (CWF19 like cell cycle control factor 1) gene was
found in a Turkish family [35].
Cwf19l1 zebrafish morphants displayed reduced locomotion and an abnormal touch-
evoked escape response at 3 dpf. Defects in cerebellar structure were also observed [35].
Cwf19l1 morphants reproduced manifestations similar to those observed in patients,
but as was remarked before, it would be interesting to develop a mutant model to verify
these morpholino discoveries and search for potential treatments for this rare disease.
• EAST (epilepsy, ataxia, sensorineural deafness and tubulopathy) syndrome.
Mutations in KCNJ10 (potassium channel, inwardly rectifying subfamily J member 10),
which encodes a potassium channel, cause EAST (epilepsy, ataxia, sensorineural deafness
and tubulopathy) syndrome (also called SeSAME syndrome) [36,37].
Morphants for the two KCNJ10 genes in zebrafish, kcnj10a and kcnj10b, have been
generated. Kcnj10a morphants were shown to have a normal phenotype but demonstrated
a statistically significant increase in the frequency of spontaneous contractions at 30 hpf.
Abnormal frequency of spontaneous contractions was rescued upon co-injection of human
KCNJ10 mRNA, but not with human mRNA containing a mutation associated with EAST
syndrome. Kcnj10a morphants displayed a touch-evoked escape response characterized by
frequent circling or loops around their vertical axis. Locomotion was aberrant with kcnj10a
morphants attempting to maintain an upright posture, with excessive fin movements
that did not accompany locomotion. Moreover, kcnj10a morphants had an increased
frequency of abnormal movements of the eyes and jaw. Aberrant locomotion and abnormal
facial movements could indicate ataxia. Sometimes, kcnj10a morphant embryos displayed
seizures that were consistent in bursts of speed with continuous swimming, even when they
hit the wall, followed by an immediate complete loss of posture. Immunohistochemistry in
kcnj10a morphants did not reveal any defects in the central or peripheral nervous systems,
meaning that locomotion defects were due to physiological defects caused by the loss of
kcnj10a. Co-injection of p53 morpholino did not rescue the locomotion defect. Pronephric
duct was found to be dilated in kcnj10a morphants. Pericardial edemas were also seen
and were probably induced by water retention. Injection of a fluorescent dextran was
performed in order to analyze the ability of morphants to excrete water. At 24 h 91% of the
water was excreted by wild type embryos, whereas the kcnj10a morphants were only able to
excrete 26%. Kcnj10b morphants were smaller and displayed morphological abnormalities,
however, locomotion was impossible to analyze due to their severe phenotype. Co-injection
with p53 morpholino did not rescue this severe phenotype in kcnj10b morphants [37].
Epilepsy was demonstrated in the same kcnj10a morphant at 120 hpf using an electroen-
cephalogram. Interestingly, pentobarbitone treatment effectively suppressed the dominating
seizure activity in kcnj10a morphants and diazepam treatment had no effect [79].
In a more recent study, co-injection of the kcnj10a morpholino with mRNA from
patients with KCNJ10 mutations related to autism spectrum disorder and epilepsy did not
rescue the phenotype, while normal human KCNJ10 mRNA did. Moreover, overexpression
of one mutation for the autism–epilepsy phenotype produced a similar abnormal locomotor
behavior [80].
Zebrafish morphant models of EAST syndrome seem to recapitulate locomotor fea-
tures of the disease, revealing epilepsy and ataxia, however, sensorineural deafness and
tubulopathy were not demonstrated. However, the generation of permanent mutant mod-
els will allow for studying the course of pathology at juvenile ages and not only during the
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embryonic stage. Interestingly, the kcnj10a morphants have been demonstrated to be useful
for testing candidate drugs.
• Poretti–Boltshauser syndrome.
A mutation in LAMA1 (laminin subunit alpha 1) causes cerebellar dysplasia with
retinal dystrophy [38].
Lama1 morpholinos caused a dose-dependent phenotype that started at 36 hpf and
was characterized by a shortened body, an abnormal body axis curvature, and malformed
eyes that often lacked lenses and had misshapen pupils. Histological analysis of lama1
morphants revealed reduced eye size, lens degradation with lenticular bladder cells form-
ing a deposit in the subretinal space and corneal thickening at 72 dpf but not in previous
stages [81].
A lama1 knock-out model created using ENU mutagenesis showed defects in retinal
ganglion cell axon guidance, including aberrant ipsilateral and anterior projections [82].
Furthermore, the anterior and postoptic commissures were not properly formed in lama1
mutants. Interestingly, expression analysis of axon guidance genes showed that said genes
were not altered in the mutant. Increased apoptosis was revealed in the forebrain of lama1
mutants. There were also defects in the guidance of neurons of the bilateral nuclei and neu-
rons of the nucleus of medial longitudinal fascicle. Reticulospinal axons showed aberrant
trajectories and Mauthner axons displayed pathfinding defects. Spinal motor neurons also
showed multiple axon guidance errors and increased branching. Branchiomotor neurons
showed failed migration but not defects in axon outgrowth. The rest of the peripheral
sensory pathways were normal and neural crest cell migration was not affected [83].
Other Lama1 zebrafish mutant models revealed impaired notochord differentiation [84]
and an ocular phenotype with irregularly shaped pupils accompanied with a shortened
body axis and lethality (all the homozygous larvae die before 12 dpf) [85]. Histological
analysis revealed defects in lens development at 30 hpf with disrupted epithelial cell mor-
phogenesis and an association of the membrane blebbing with the lens capsule. At 36 hpf,
apoptotic cells were distinguishable in the lens, fiber cell morphogenesis and retinal lami-
nation were delayed, and the cornea was dysplastic. Lama1 mutants were compared with
wild type embryos, in which the lens was ablated at 24 hpf. At 10 dpf lama1 mutants and
lens ablated embryos showed significantly narrowed pupils. However, anterior segment
dysgenesis was more pronounced in lama1 mutants and the cornea showed focal dysplasia
in the mutants but not in lens ablated embryos. This indicates that these differences were
probably caused by the loss of lama1 and not loss of the lens. Focal adhesions were reduced
in the lens epithelium and cornea of lama1 mutants. Moreover, lama1 morpholino embryos
had multiple axonal projection defects in ganglion cells within the eye. In lama1 mutants,
mispositioned photoreceptor cells in the inner retina were detected. These defects were
not observed in lens ablated embryos. Furthermore, Lama1 morphants displayed delayed
endothelial cell differentiation and severe dysmorphogenesis of the hyaloid vasculature.
Tissue-specific genetic mosaics were created through blastula transplantation of lama1
mutant cells or wild type cells in the region of the embryo that gives rise to ocular tissue.
Chimeras, in which a half of the cells of the eye were from donor embryos, were raised to
adulthood. Lama1 mutant chimeras showed reduced embryo survival compared to wild
type chimeras. Moreover, lama1 mutant adult chimeras displayed ocular defects, such as
severe dysplasia, microphthalmia, cataracts, lens dysmorphogenesis, small irregular pupils,
disrupted scleral iridophore patterning, and iridocorneal dysgenesis. Adult wild type fish
with their lenses removed showed reduced eye size at 24 hpf, small irregular pupils and a
dysmorphic ciliary canal but the other structures developed normally [85]. In addition, the
optokinetic response of lama1 mutants was severely reduced at 5 dpf [86].
Using a lama2 mutant with injection of lama1 morpholinos revealed a complete loss of
laminin immunoreactivity within the myotome, a high number of detached muscle fibers
and reduced muscular birefringence, which suggests a requirement for lama genes in early
muscle attachment [87].
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Furthermore, lama1 zebrafish mutants were used to study optic cup development.
Although optic cup size was normal in lama1 mutants, time lapse analysis of the optic
cup revealed disrupted morphogenesis at 12.5 hpf. The mutant optic vesicle was rounder
and more symmetric along the anterior–posterior axis than in controls. The retina was
disorganized, and the neural retina and retinal pigmented epithelium were not able to
enwrap the lens. The lens was ovoid rather than spherical and the choroid fissure failed to
form properly. Moreover, in lama1 mutants the connection between the brain and optic cup
failed to constrict. Focal adhesion recruitment in lama1 mutants was reduced at the optic
stalk furrow, however, it was increased at the lens retina interface during invagination,
meaning that lama1 has a role in the negative regulation of focal adhesion assembly during
invagination. Apoptosis was observed in medial regions of the optic cup in lama1 mutants.
However, injection of p53 morpholino failed to rescue cell death. Lama1 was not required
for protrusive cell behaviors, as lama1 mutants displayed normal cell behaviors although
retinal structure was abnormal. Cell polarity during optic vesicle evagination was observed
to be disrupted in lama1 mutants [88].
Lama1 zebrafish morphants and mutants have been widely used to study defects in
retinal, notochord and optic cup development. However, only defects in the forebrain
were reported [83] and the rest of the CNS, including the cerebellum, was not broadly
investigated [83]. Future research of the CNS in these lines could reveal if they represent
an appropriate model to study cerebellar dysplasia or if they are only useful for studying
retinal dystrophy.
• Mitochondrial recessive ataxia syndrome (MIRAS).
POLG (mitochondrial DNA polymerase gamma) mutations cause MIRAS [39,40].
A zebrafish polg mutant model showed significantly reduced mitochondrial DNA
(mtDNA) levels, starting at 1 week post fertilization (wpf) and remaining severely reduced
until their death prior to 4 wpf. Reduced levels of Vdac1 (voltage dependent anion
channel 1)—a protein found on the outer mitochondrial membrane—were revealed in polg
mutant larvae, which could be related to a lower mitochondrial mass. Despite reduced
mitochondrial mass, ATP levels and static lactate levels, which indicate glycolysis, were
not affected in polg mutants. Polg mutant larvae were smaller, thinner and had smaller
eyes than wild type larvae and polg heterozygous mutant larvae. Moreover, polg mutants
also displayed deficient fin regeneration after amputation at 2 wpf. An in vivo mtDNA
polymerase activity assay revealed that polg mutants were unable to activate mtDNA
replication since mtDNA remained depleted. Interestingly, the relative abundance of
mtDNA was found to be higher in the tail tissue than in the gills, heart, internal organs
and CNS tissues in all genotypes. Moreover, the CNS tissue levels of mtDNA were lower
compared to those of the gills, heart and internal organs. Polg mutant mtDNA levels were
significantly reduced in all of the analyzed tissues, with the organ tissues being the most
significantly affected and the tail tissues being less affected, as compared with the wild
type and heterozygous mutants. The oxygen consumption rate measurements showed that
the mitochondria in polg mutants maintained similar levels of spare respiratory capacity.
However, the respiratory basal levels of homozygous polg larvae of 3 wpf were reduced in
the CNS, with a low respiratory output [89].
Recently, Facchinello and colleagues [90] developed polg morphants and knock-out
mutants with ENU and CRISPR/Cas9. However, the polg CRISPR/Cas9 line did not
survive until adulthood and was less studied. Reduced body length was observed in these
three zebrafish models. Polg morphants had an enlarged cardiac atrium and demonstrated
an alteration of pathways involved in mitochondria–nucleus retrograde signaling. Polg
knock-out ENU displayed cardiac defects (dilated heart and reductions in the trabecular
network and its thickness), gonadal defects in both sexes (alteration in follicle maturation
and smaller testes with reduced sperm levels) and had a reduced liver size. Birefringence
assays in polg ENU mutants revealed defects in skeletal muscle. Moreover, an altered
mitochondrial distribution, a reduction in mitochondrial mass and mtDNA expression,
and a decreased oxygen consumption rate and mitochondrial superoxide production
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were also observed in the same model. Alterations of mitochondria–nucleus retrograde
signaling were also observed in both mutant lines. In addition, polg CRISPR/Cas9 mutants
developed early defects in skeletal muscle and showed altered responsiveness to light
stimuli at 15 dpf. Finally, clofilium tosylate (a potassium channel blocker) treatment of polg
ENU mutant larvae restored mtDNA levels. Treatment of adult polg mutants efficiently
rescued complex I respiratory activity, mitochondrial mass and skeletal muscle defects. In
polg morphants, cardiac frequency and atrium size was also restored by treatment with
clofilium tosylate [90].
Polg morphants and mutant zebrafish lines show characteristics of mitochondrial
disease. However, the only reference to the CNS in these studies was altered locomotion
and the presence of reduced respiratory levels, which may be indicative of neuronal
damage. On the other hand, treatment with clofilium tosylate seemed to alleviate part of
the organ damage due to polg depletion. Future analysis of this model will reveal if defects
exist in the CNS that recapitulate the neural damage observed in MIRAS.
• Pancreatic and cerebellar agenesis (PACA).
Mutations in PTF1A (pancreas transcription factor 1alpha) cause PACA [41].
The Ptf1a gene in zebrafish has been broadly studied, especially in pancreas develop-
ment. Downregulation of ptf1a by morpholinos showed no gross morphological phenotype
but led to a lack of differentiated exocrine cells and reduced trypsin expression. However,
the morpholino did not affect the expression of the endocrine markers insulin, glucagon
and somatostatin [91]. At 80 hpf, ptf1a morphants lacked an exocrine pancreas and they
only had a rudimentary pancreatic duct. At this stage, carboxypeptidase A-producing cells
had no detectable expression, although islet organization was normal. Moreover, ptf1a
morphants had fewer anterior endocrine cells, which are located in the exocrine pancreatic
parenchyma [92]. A hypomorphic ptf1a zebrafish mutant model showed delayed ventral
pancreas specification, loss of exocrine cells and an increase in ectopic endocrine cells.
These data indicate that ptf1a is involved in endocrine and exocrine fate specification [93].
Interestingly, ptf1a was also seen to play an important role in retinal development.
Knock-down of ptf1a caused a reduction in the number of horizontal and amacrine cells.
This reduction in cell numbers was not caused by increased apoptosis. However, cells that
normally become amacrine and horizontal cells, changed their inhibitory neuronal fate
into excitatory cell types, such as photoreceptors, bipolar, and ganglion cells, the numbers
of which were significantly increased [94]. Injection of ptf1a morpholino into a ptf1a mutant
line with fewer amacrine cells led to a total lack of amacrine cells. Despite the lack of
amacrine cells, phalloidin staining indicated that an F-actin-rich inner plexiform layer-like
neuropil was still able to form in these retinas, although it was thinner than in controls [95].
These studies using zebrafish models reveal an important role for ptf1a in the specification
of retinal cells.
Defects in the brain of zebrafish were not reported in ptf1a morphants and mutants
(see previous paragraphs). However, the generation of a transgenic ptf1a zebrafish line
suggested that transcription factors and enhancers not only regulate the activation of
Ptf1a expression in the developing pancreas, but also in the hindbrain, spinal cord and
cerebellum [96]. New studies should focus on the use of these or similar zebrafish models
to decipher the role of Ptf1a in the brain and spinal cord.
• Gordon Holmes syndrome.
Mutations in the RNF216 (ring finger protein 216) gene alone or in combination with
mutations in OTUD4 (OTU deubiquitinase 4), which are involved in ubiquination, are the
cause of Gordon Holmes syndrome [42].
Knock-down of the rnf216 gene in zebrafish via the use of morpholinos resulted in a
reduction in the size of the eye cup and optic tecta, disorganization of the cerebellum and
a slight reduction in head size. This phenotype was rescued by co-injection with human
RNF216 mRNA but not with the human mRNA with mutations related to Gordon Holmes
syndrome. Knock-down of zebrafish otud4 also resulted in a reduction in the size of the
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optic tecta and cerebellum. Co-injection of rnf216 and otud4 morpholinos produced a more
severe cerebellar phenotype, accompanied with an increased reduction in the size of the
optic tecta and marked microphthalmia. Co-injection of human RNF216 or OTUD4 mRNA
in double morphants rescued the phenotype, but this was not the case for co-injection of
mutant RNF216 or OTUD4 mRNA alone. These data suggest that epistatic interactions
between these mutations contribute to the disease phenotype [42].
Zebrafish morphants of rnf216 and otud4 showed cerebellar damage characteristic of
Gordon Holmes syndrome that should be reproduced in a zebrafish mutant model. The
presence of cerebellar abnormalities indicates that these might be interesting models to
search for a possible treatment for this syndrome, such as the possibility of performing an
unbiased drug screen.
• Childhood-onset neurodegeneration with ataxia, dystonia, and gaze palsy (NADGP).
Biallelic mutations in the SQSTM1 (sequestosome 1) gene, which is required for
intracellular signaling, the oxidative stress response, apoptosis and autophagy, cause
NADGP. Dominant mutations in SQSTM1 have been also related with Paget’s disease of
the bone, amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD) [43].
Knock-down of the sqstm1 gene in zebrafish led to abnormal motor behavior consistent
with a reduced touch-evoked escape response. Motor neuron axons were seen to suffer
disrupted arborization and shortening. However, there was no neuronal loss or Mauthner
cell defects in sqstm1 morphants. Co-injection of human SQSTM1 mRNA rescued the
phenotype but this was not rescued by the co-injection of human SQSTM1 mRNA with
ALS/FTD mutations. Moreover, overexpression of wild type and mutant human mRNAs
did not reproduce the morphant phenotype. As SQSTM1 is known to regulate the activity
of mTOR (regulates responses to DNA damage), mTOR levels were measured in sqstm1
morphants and increased levels of mTOR were found. Treatment with rapamycin (an
mTOR inhibitor) at 48 hpf resulted in amelioration of the motor phenotype of sqstm1
morphants [97].
In addition, sqstm1 knock-down in a splice site related with cerebellar ataxia, induced
structural cerebellar defects in 60% of the embryos which that were specific (as no other
phenotypic defects were found). These cerebellar defects ranged from depletion of the
axonal connections across the midline of the cerebellum to complete atrophy. These
cerebellar phenotypes were rescued by the co-injection of human SQSTM1 mRNA, but not
with the co-injection of human SQSTM1 mRNA with disease mutations [43].
The presence of locomotor defects and cerebellar abnormalities make these morpholi-
nos interesting for future studies that compare these findings with new mutant models and
to search for treatments that can rescue these specific phenotypes.
• Spinocerebellar ataxia autosomal recessive type 7 (SCAR7) and ceroid lipofuscinosis
neuronal 2 (CLN2).
TPP1 (tripeptidyl peptidase 1) is a serine protease mainly expressed in the lysosome
and melanosome. TPP1 mutations have been linked with SCAR7 and CLN2. It has been
proposed that loss of function variants with abolished TPP1 enzyme activity leads to CLN2
disease, whereas variants that diminish TPP1 enzyme activity lead to SCAR7 [44].
Morpholino knock-down of tpp1 in zebrafish causes severe developmental defects
starting at 28 hpf with an abnormal head and increased apoptosis throughout the body. At
52 hpf, tpp1 morphants developed curly tails and cardiovascular defects such as cardiac
loop malformation, pericardial edema, reduced cardiac contractility and low blood flow
through the heart [98].
More recently, a knock-out of the tpp1 gene was observed to recapitulate the patho-
logical and behavioral features of CLN2 disease. Tpp1 mutant zebrafish defects started
at 48 hpf with a curved body, reduced head and a smaller retina. At 72 hpf, there was
no detectable jaw and at later stages the swim bladder was not present in tpp1 mutants.
In addition, tpp1 mutants died prematurely before 7 dpf. Stored levels of subunit c of
mitochondrial ATP synthase in lysosomes, which is a characteristic of CLN2 disease, were
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observed to be increased in the whole body including the eye, head, spinal cord, and
most prominently, the muscle fibers in 48 hpf tpp1 mutants. CNS examination revealed
a deep absence of HuC/D-positive differentiated neurons in the retina, optic tectum and
cerebellum of tpp1 mutants and tpp1 morphants. Moreover, astrocytosis was observed
in the thalamus and cerebellum of tpp1 mutants at 48 hpf. Selective apoptosis was seen
in the retina, optic tectum, cerebellum and spinal cord in tpp1 mutants at 48 hpf. This
selective apoptosis is similar to that found in human patients of CLN2 disease. Decreased
proliferation was shown at 48 hpf in the retina, forebrain, midbrain–hindbrain boundary
and spinal cord of tpp1 mutants and tpp1 morphants. Axonal disorganization, which is
another feature of CLN2 disease, was shown to start at 48 hpf in tpp1 mutants and tpp1 mor-
phants. Axonal disorganization in tpp1 deficient zebrafish was characterized by posterior
commissure defasciculation, absence of the trochlear nerve and almost complete absence
of the optic nerve, which failed to send fibers to the optic tectum. No axonal defects were
seen before 48 hpf and primary axon tract formation was not affected in tpp1 deficient
models, meaning that axonal loss was secondary to degenerative changes. Locomotion
was impaired in tpp1 mutants at 72 hpf. Mutants had an aberrant swimming pattern
demonstrating many turns, a significantly increased hyperactive behavior covering long
distances, and seemed to show convulsions. At 96 hpf, tpp1 mutants displayed sustained
muscle contractions and lost the ability to move. The touch-evoked escape response was
also reduced in tpp1 mutants [99]. Seizure activity in tpp1 mutants was demonstrated
through single electrode electroencephalography. Treatment with valproate, but not with
pentobarbitone, significantly reduced seizure-related movement and reduced the mortality
between 3 and 6 dpf [100]. This exhaustive research and the positive results obtained with
valproate open up the possibility of performing high throughput drug screen against CLN2
in tpp1 zebrafish mutants.
• Spinocerebellar ataxia autosomal recessive type 24 (SCAR24).
Biallelic mutations in the UBA5 (ubiquitin-activating enzyme of UFM1) gene were
recently seen to cause SCAR24 [45] and early onset encephalopathy with intellectual defi-
ciency, microcephaly, movement disorders, and epilepsy [101]. Studies in fibroblasts from
affected individuals showed that UBA5 mutations impaired the process of UFMylation,
resulting in an abnormal endoplasmic reticulum structure [101].
Injection of uba5 morpholinos in zebrafish embryos did not result in a morphological
phenotype. However, locomotion defects were observed in these morphants. Uba5 mor-
phants had reduced movements and difficulties to exit the chorion in comparison with wild
type larvae. The touch-escape response of uba5 morphant larvae at 72 hpf was decreased.
Larvae exhibited looping or pinwheel swimming which resembled a seizure-like behavior.
The spontaneous motility of uba5 larvae at 5 dpf was observed to be severely affected [101].
The next necessary step will be to develop a uba5 zebrafish mutant line to reveal whether
it recapitulates the uba5 morpholino locomotion defects. More research is also needed to
understand the cellular/molecular/physiological defects caused by uba5 knock-down.
• Galloway-Mowat syndrome.
Galloway-Mowat syndrome is caused by mutations in the WDR73 (WD repeat domain 73)
gene, which has high levels of expression in the brain, mainly in the cerebellum [46].
A Galloway-Mowat syndrome zebrafish model was generated using wdr73 morpholi-
nos. Wdr73 morphants demonstrated a reduced head size, brain morphology defects,
hypopigmentation—which displayed incomplete penetrance—and a curved body or trun-
cated tail region at 1–2 dpf. Wdr73 morphants lacked expression of dmbx1a, which is related
to midbrain progenitor cells, in the cerebellum at 48 hpf but not at 24 hpf. At 48 hpf, wdr73
morphants had a poorly expanded and differentiated midbrain. However, fgf8 (fibroblast
growth factor 8) expression, which is a marker of progenitor cells of the midbrain-hindbrain
boundary, was equal to that of wild type embryos. Morphogenesis of the midbrain and
hindbrain was disrupted in wdr73 morphants, leading to dilated ventricles. Proliferation
of progenitor cells was also reduced in wdr73 morphants at 1 dpf. Purkinje cells in wdr73
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morphants were absent at 4 dpf. This cerebellar phenotype was rescued in all the larvae
co-injected with zebrafish wdr73 mRNA and in the majority of larvae co-injected with
human WDR73 mRNA. In contrast, co-injection with human mRNA containing a nonsense
mutation related to Galloway-Mowat syndrome did not rescue the phenotype [46]. As
was previously mentioned for other morpholino models, the creation of mutant lines that
recapitulate the cerebellar phenotype is fundamental to progress research in this area,
especially when morpholinos cause severe morphological defects such as in this case.
• Spinocerebellar ataxia autosomal recessive type 12 (SCAR12).
SCAR12 is produced by mutations in the WWOX (WW domain containing oxidore-
ductase) gene, which has functions in DNA repair and acts as tumor suppressor gene [48].
Tsuruwaka and colleagues used morpholinos and siRNA to knock-down zebrafish
wwox to study intracellular Ca2+ dynamics. Wwox knock-down caused severe edemas,
curled backbones, reduced body length, head and eye size and increased lethality in
embryos. In addition, these models had altered Ca2+ dynamics [102]. This model presented
developmental delay, which is a characteristic of SCAR12 and also had disturbed Ca2+
dynamics, which remarks the wwox role in DNA repair. However, the CNS was not studied
and locomotion assays to evaluate epilepsy were not performed. Future studies looking at
these aspects will inform us as to whether zebrafish can be a good model for SCAR12.
3.3. Recessive Inherited Disorders Related to Ataxia
In this section we discuss several zebrafish models designed to model pathologies that
present ataxia as one of their symptoms: Niemann–Pick disease type C (NPC), CAMRQ3,
Joubert syndrome and pontocerebellar hypoplasia.
• Niemann–Pick disease type C (NPC).
NPC is a rare neurodegenerative lysosomal storage disorder caused by mutations
in the NPC1 (95% of the cases) or NPC2 genes, which are involved in cholesterol traffick-
ing. The clinical diagnosis requires fibroblast staining with filipin to determine whether
accumulation of unesterified cholesterol in lysosomes is present [50].
Morpholino knock-down of npc1 in zebrafish led to developmental delay characterized
by a reduced progression of epiboly. Co-injection with Npc1 mouse mRNA rescued the
epiboly delay. When the npc1 morpholino was injected in the yolk syncytial layer at
1000 cell stage, epiboly was delayed more often. This means that npc1, expressed in the
yolk syncytial layer, is critical for normal epiboly movements. Analysis of mesoderm
induction and cell fates revealed that both develop normally in npc1 morphants. Actin
cytoskeleton disorganization was also observed in npc1 morphants, with actin clumping
in some cells and localized loss of actin microfilaments in other cells. Treatment with
the steroid hormones pregnenolone and Dex in npc1 morphants partially rescued epiboly
delay and actin cytoskeleton defects, suggesting that a reduction in steroidogenesis was,
in part, responsible for the epiboly delay phenotype in npc1 morphants. Npc1 morphants
that completed epiboly presented a phenotype characterized by shorter body axis, wider
notochord and somites and died before 2 dpf. Apoptosis increased in npc1 morphants
at 1 dpf. In addition, npc1 morphants displayed punctate sterol distribution in cells after
filipin staining at 12 hpf [103].
Since thrombocytopenia is found in some patients with NPC1, this symptom was
also studied by Louwette et al. [104] in npc1 morphants. Zebrafish injected with npc1
morpholinos had malformed heads and dysmorphic brains and eyes. Filipin staining
revealed defective intracellular processing of cholesterol. Study of thrombocytes revealed
that, even with a low dose of morpholino, 82% of the embryos had an almost complete
absence of thrombocytes in the caudal hematopoietic tissue at 3 dpf. When the dose was
doubled, 90% of the embryos had thrombocytopenia and died at 5 dpf. Erythrocytes
numbers were significantly reduced in npc1 morphants [104].
The generation of a npc1 stable mutant model using CRISPR/Cas9 was able to re-
produce some of the symptoms of human patients. Npc1 mutant zebrafish had a reduced
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lifespan; the majority of them died before 2 months post-fertilization and none of them
survived after 8 months. Moreover, npc1 mutants had a reduced body length and exhibited
ataxia symptoms. Histological analyses allowed for the observation of macroscopic hep-
atomegaly and splenomegaly with foamy and vacuolated liver cells. Lipid accumulation
in the livers of npc1 mutants and a massive accumulation of cholesterol in hepatocytes was
also observed. A lipid profile analysis of liver tissues revealed significant differences in npc1
mutants in profiles of ceramide, diacylglycerol, lysophosphatidic acid, phosphatidic acid,
phosphatidylcholine, phosphatidyl ethanolamine, phosphatidyl serine and triglyceride, as
compared to wild types. Interestingly, seven ceramides—which are characteristic of NPC1
disease—were accumulated in the liver of npc1 mutants. Finally, calretinin expression was
significantly reduced in the cerebellum of npc1 mutants at two months post-fertilization,
which indicates a loss of Purkinje cells [105].
Tseng et al. [106] also generated a CRISPR/Cas9 npc1 model that had reduced lifespan
(died before 6 months of age), infertility and reduced body length compared to wild type
fish. Moreover, adult npc1 mutants failed to maintain balance during swimming and died a
few days after the balance defect was observed. Histopathological analyses revealed axonal
spheroids in the hindbrain of adult npc1 mutants and disorganized Purkinje neurons in
the cerebellum. The first sign of liver disease appeared at 7 dpf in npc1 mutants. They had
bigger, dark and opaque livers as compared to wild type larvae. Histopathological analysis
of liver sections showed larger hepatocytes full of vacuole like structures in npc1 mutants.
In addition, filipin staining demonstrated cholesterol accumulation in npc1 mutant liver
tissue. Surprisingly, lipid accumulation was not observed in npc1 mutants. Filipin positive
staining started at 2 dpf in npc1 mutants in the yolk area and at 3 dpf in lateral line tissues.
By 5 and 7 dpf, npc1 mutants accumulated more unesterified cholesterol throughout the
entire trunk area. Cholesterol accumulation was observed along the notochord and the
ventral edge of the trunk in npc1 mutants. Application of a pCS2+ plasmid with npc1 cDNA
and EGFP rescued the unesterified cholesterol accumulation in the yolk area. Lysosomes
in live larval zebrafish were observed using LysoTracker Red staining. At 5 dpf, Npc1
mutants had a stronger LysoTracker Red staining signal compared to wild type larvae,
mainly in the neuromasts and in the olfactory placode of npc1 mutants at 3 dpf. Based on
these results, LysoTracker Red staining was used to test drug efficacy in vivo. The 2HPβCD
compound, which was seen to be effective in other animal models and had been tested
in humans, was tested on 3 dpf larvae. After 3 days of treatment, a significant reduction
in LysoTracker Red staining was observed in npc1 mutants. Filipin staining also revealed
reduced accumulation of cholesterol in npc1 mutants. However, the 2HPβCD treatment
did not rescue the liver defects or improve survival [106]. In any case, the development of
a method to test compounds in npc1 mutant zebrafish is crucial for attempting to discover
new therapies for NPC.
• Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3
(CAMRQ3).
Mutations in carbonic anhydrase 8 (CA8) are related to CAMRQ3 [51]. CA8 is a
catalytically inactive isoform belonging to the zinc-containing metalloenzymes family, that
catalyzes the reversible hydration of carbon dioxide [52].
The ca8 gene was found to be strongly expressed in the zebrafish nervous system,
and specifically, in the Purkinje cells, which correlates with the observed expression in
Purkinje cells in humans and mice. Ca8 morpholinos caused defects in the zebrafish head
as early as 9 hpf and increased mortality. At 1 dpf, ca8 morphants had defects in the
head, a fragile body, curved tail, small eye size and pericardial edema that were dose-
dependent [52,107]. As development advanced, defects such as the shortened tail, curved
body axis, absence of swim bladder became more obvious. The swimming pattern was
altered even with a low morpholino dose. Ca8 morphants swam at a slower speed, showed
an increased turning angle, and most of them swam along the periphery of the Petri dish.
Furthermore, ca8 morphants had a pronounced difficulty in balancing the body while
swimming compared with wild type. When the concentration of ca8 morpholino was
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increased, the larvae progressively lost their ability to swim, until higher doses caused a
complete loss. The co-injection of a p53 morpholino did not rescue the phenotype defects
or mortality rates. Gross morphological changes in the cerebellar region and a reduction
in the size of the cerebellum was observed in ca8 morphants. Moreover, ca8 morphants
showed abnormal muscle development and apoptosis in the head region and periphery
of the tail region [52]. Touch-evoked responsiveness was also reduced in ca8 morphants
due to defective cerebellar function, as no defects were observed in the motor neurons
or Rohon Beard sensory neurons [107]. Ca8 zebrafish morphants seem to reproduce the
typical features observed in CAMRQ3. As with other disorders, it would be of interest to
develop a stable zebrafish mutant model that reproduces these (or similar) phenotypes.
• Joubert syndrome.
Joubert syndrome consists of a group of early onset recessive or X-linked cerebellar
ataxias with a characteristic mid-hindbrain malformation called the molar tooth sign [53].
More than 30 genes have been associated with Joubert syndrome. Several zebrafish models
have been created to study some of these genes, but most of them were focused solely on
their function in ciliogenesis or retinal development [108–114].
Mutations in the AHI1 (Abelson helper integration site 1) gene are the most common
cause of Joubert syndrome. Knock-down of ahi1 in zebrafish caused a curved body and ab-
normalities in the development of the eye, hindbrain (hydrocephalus) and otoliths, together
with defects in cyst formation in the pronephric kidney tubules. These malformations were
comparable to those of patients with Joubert syndrome. Co-injection of murine Ahi1 mRNA
efficiently rescued the phenotype. Histological analyses revealed defects in lamination of
the cell layers of the retina in ahi1 morphants. Reversed cardiac looping with the heart in
a L-loop pattern was found in ahi1 morphants. Moreover, cloacal dilatation and loss of
pronephric cilia was observed in the pronephric ducts [115].
More recently, Lessieur et al. [116] generated an ahi1 TALEN mutant model and
showed that mutants had cone degeneration and rhodopsin mislocalization in rods at
5 months of age as well as absence of distal pronephric duct cilia [116]. Zhu et al. [117] used
zebrafish morpholinos and CRISPR/Cas9 mutants to analyze if ahi1 mutations lacking
the intact WD40 repeats affect axonal decussation. They found that ahi1 morphants and
mutants had retinal ganglion cell axon misprojection and ocular dysplasia caused by a
toxic gain of function [117].
Other zebrafish models of different genes related to Joubert syndrome, such as a
knock-down model of cep290 (centrosomal protein 290), also recapitulate features of Joubert
syndrome, such as cerebellar abnormalities, hydrocephalus, retinal defects, abnormalities in
otic cavity development and pronephric cysts [118,119]. Moreover, cep290 morphants were
used to search for therapies for ciliopathic renal disease, which resulted in the discovery
that rapamycin and roscovitine ameliorate the symptoms [120]. More recently, a mutant
line was developed to study retinal degeneration. Cep290 mutants presented scoliosis and
progressive cone deterioration [114].
Similarly, knock-down of cspp1 (centrosome and spindle pole associated protein 1),
cep104 (centrosomal protein 104), kiaa0556 (katanin interacting protein) and poc1b (proteome
of the centriole 1B) in zebrafish resulted in a ciliopathy phenotype, which is characteristic
of Joubert syndrome [121–126].
Most of these Joubert syndrome zebrafish models were not used to study the CNS.
In addition, most of them were not created with mutants that we suspect would probably
reproduce better the traits of this syndrome.
• Pontocerebellar hypoplasia.
Pontocerebellar hypoplasia constitutes a group of early onset rare neurodegenerative
disorders with variable symptoms of cerebellar ataxia. Several mutations in different genes
have been associated with different forms of pontocerebellar hypoplasia. Mutations in
TSEN54, a tRNA splicing endonuclease subunit gene, were associated with pontocerebellar
hypoplasia type 6 and late onset dominant hereditary ataxia [54].
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Morpholino knock-down of tsen54 in zebrafish resulted in brain hypoplasia and loss of
structural integrity inside the brain with an aberrant mid-hindbrain boundary. Co-injection
of human TSEN54 mRNA partially rescued the brain phenotype. Co-injected embryos
displayed milder brain hypoplasia and a more defined brain structure. Interestingly, tsen54
morpholino abnormalities were not associated with neurodevelopmental patterning defects
since expression of fgf8 (which plays a role in the maintenance and development of the
mid-hindbrain boundary) and otx2 (orthodenticle homeobox 2) (which functions in the
early regionalization of the mesencephalon) at 24 hpf was normal. Tsen54 morphants had
increased levels of apoptosis in the brain. A stable tsen54 knock-out model created with
ENU mutagenesis had a reduced survival rate with all the tsen54 homozygous larvae
dying before 9 dpf. However, the defects that caused their lethality were not studied
and it is not known if mutations in tsen54 also caused brain hypoplasia. In addition,
knock-down of the rars2 (arginyl-tRNA synthetase 2) gene, which has been also related to
pontocerebellar hypoplasia type 6, resulted in a similar brain phenotype to that observed
in tsen54 morphants, which was also partially rescued by the co-injection of RARS2 human
mRNA [127]. The better characterization of the mutant model would help to study the
molecular consequences of pontocerebellar hypoplasia.
Mutations in the SLC25A46 (solute carrier family 25 member 46) gene, which plays a
role in mitochondrial dynamics, have been also related to pontocerebellar hypoplasia and
progressive myoclonic ataxia with optic atrophy and neuropathy [128,129].
Slc25a46 was observed to be prominently expressed in the brain and the spinal cord
during zebrafish embryonic development. Consistent with this, slc25a46 zebrafish mor-
phants showed a neurodegenerative phenotype with a failure of the development of the
midbrain and hindbrain, severe curly tail morphology and abnormal locomotion. Motor
neurons had significantly shorter axon tracts and many of them failed to innervate the
rostral myotome at 48 hpf, the spinal cord neuropil had fewer neuronal processes, fewer
retinal ganglion cell axons reached the tectum at 72 hpf, and retinal ganglion cell dendrites
were also affected. Degeneration of motor neuron terminals was also observed. Slc25a46
zebrafish morphants presented a misallocation of the mitochondria, which were in the
process of fission within the cell bodies. This suggested that incomplete fission of mito-
chondria in slc25a46 morphants might inhibit transport and distribution into neuronal
processes. Mitochondrial dynamics were studied in dissociated neurons from slc25a46
zebrafish morphants. Mitochondria from morphants were longer than those of wild type
embryos and were immobile. Co-injection with SLC25A46 human mRNA restored the size
of the mitochondria but not the co-injection with mutant SLC25A46 mRNA. On the other
hand, overexpression of the wild type mRNA resulted in mitochondrial fragmentation and
disruption of the mitochondrial network [129,130].
In contrast to the morphant studies, a CRISPR/Cas9 slc25a46 zebrafish model showed
no phenotype because of genetic compensation, as was demonstrated by RNA sequencing.
Injection of a slc25a46 morpholino into an F2 homozygous slc25a46 zebrafish CRISPR/Cas9
line did not cause a phenotype. However, F0 embryos injected with an slc25a46 CRISPR/Cas9
construct had a phenotype that resembled slc25a46 morphants since they had smaller
eyes, heart edema, a shorter trunk and an increase in motor neuron axon disruptions in
comparison with wild types. The F0 slc25a46 CRISPR/Cas9 phenotype was rescued after
the co-injection of SLC25A46 human mRNA. The existence of a phenotype in slc25a46
CRISPR/Cas9 mosaics of the F0 generation, but not in the homozygous F2 generation,
indicates that the genetic compensation starts after the F0 generation. RNA sequencing
showed a high number of serine proteases and their transcription factors, serine protease
inhibitors, DNA-binding proteins and a smaller number of transporters, proteins related
to immunity that were expressed differentially in F2 slc25a46 CRISPR/Cas9 embryos at
48 hpf [131]. In this case, it seems that the slc25a46 morphant model better represents the
main features of pontocerebellar hypoplasia caused by mutations in SLC25A46 (and not
the mutant homozygous model that suffers genetic compensation). This morphant model
will help to further study pontocerebellar hypoplasia and search for possible treatments.
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4. Conclusions
The majority of the zebrafish models discussed here for genes related with recessive
ataxias reproduced some of the neuronal and non-neuronal phenotypes observed in human
disorders. The models that did not develop any neuronal symptoms or locomotor deficits
were: atm morphants and mutants [55,56]; polg mutants [89,90]; ptf1a morphants, mutants
and transgenic lines [91–96]; wwox morphants and siRNA models [102]. In any case, atm
models developed other non-neuronal symptoms of AT such as radiosensitivity, infertility
and immunodeficiency [55,56]. Polg mutants, which were analyzed in order to study
mitochondrial disease, showed reduced mitochondrial numbers, reduced respiratory levels
in the CNS, and altered locomotion [89,90]. ptf1a models reproduced the pancreatic agenesis
of PACA [91–96]. wwox knock-down models, which demonstrated developmental delay,
were only used to study Ca2+ dynamics, highlighting the role of wwox in DNA repair [102].
In addition, snx14 mutants [61] did not recapitulate the snx14 morphant motor neuron
deficit phenotype [27], but revealed a role for this gene in lipid biogenesis [61].
Most of the publications of autosomal recessive ataxias employed morpholinos to
cause a knock-down and a loss of function effect. The morpholino effect is transient, its
degradation occurs in few days and can sometimes cause off-target effects. For this reason, it
is fundamental to validate it with morpholino controls (standard or mismatch morpholinos),
PCR/Western blot/immunohistochemistry and mRNA rescue. As stated above for several
models, stable mutant lines are necessary to complement morpholino studies because
they are more informative and might facilitate drug screening [62]. However, mutant
models do not always recapitulate the phenotypes observed with morphants due to genetic
compensation and maternal mRNA rescue.
Although zebrafish are not expected to fully reproduce the human phenotypes due
to their less intricate CNS and their limited number of complex behaviors, they are very
informative for unravelling gene functions and analyzing gene and molecular pathways.
In addition, their small size and external fertilization simplify high throughput drug or
genetic screening. In this review, we reported various drug treatments that alleviate the
symptoms of zebrafish models of autosomal recessive ataxias [70,79,90,97,100,103,106,120].
Future work should apply the use of these models for high throughput drug screening.
Recent technological advances in genetic editing, such as the development of CRISPR/Cas
technologies [132], will improve the number of specific stable mutant lines that better
mimic human conditions, while the use of novel techniques of microscopy and imaging,
such as super-resolution or light-sheet microscopy, in zebrafish will ease phenotypic
characterization.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cells10040836/s1, Supplementary Table S1: Description of zebrafish models of autosomal
recessive ataxias.
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